Norlase Secures $20.7M for Ophthalmic Laser Tech

Med-tech company Norlase, a 2014 spin-out of the Technical University of Denmark, has signed a €20 million ($20.7 million) venture debt financing with the European Investment Bank (EIB). The funding will support the expansion of Norlase’s innovative ophthalmic laser technology.

Norlase, a two-time PRISM Award winner and developer of ophthalmic laser technology, has secured funding to expand the commercialization of its portable ophthalmic lasers. Courtesy of Davy Denke.

On a technical level, the financing will support the development and market access of Norlase’s innovative portable ophthalmic lasers, designed to diagnose and treat causes of vision loss and blindness. The initiative focuses on advancing novel ophthalmic laser technologies and expanding production facilities to support increased demand.

The company recently launched LYNX, an ophthalmic laser device which the company said can reduce treatment time by more than 50%. Norlase was awarded a 2025 PRISM Award for the device, following another win in 2021 for its LION device. The company received nominations in 2020 for its LEAF product and in 2023 for ECHO.

The EIB financing is supported by the European Commission’s InvestEU program.